It is more important to make the resubmission watertight than to satisfy impatient shareholders. In addition, the company is, not inconceivably, building a data and manufacturing process control moat around its product and iP that will make it basically unassailable. It is in this context that we should view the wait fir resubmission and time it takes. The process control draft FDA guidance published in late Dec 2023 had many mentions of the need for a risk controlled process. I suspect the CMC module being prepared for resubmission will be beefed up in order to satisfy all of these demands.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assurance-cellular-and-gene-therapy-products
- Forums
- ASX - By Stock
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
It is more important to make the resubmission watertight than to...
-
-
- There are more pages in this discussion • 243 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B |
Open | High | Low | Value | Volume |
$1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8500 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.09 | 26954 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8500 | 1.080 |
8 | 57036 | 1.075 |
12 | 113080 | 1.070 |
6 | 49342 | 1.065 |
6 | 134320 | 1.060 |
Price($) | Vol. | No. |
---|---|---|
1.090 | 26954 | 3 |
1.095 | 71504 | 4 |
1.100 | 31504 | 2 |
1.105 | 31504 | 2 |
1.110 | 70692 | 5 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online